Ranibizumab for choroidal neovascularization following atrophic involution of adult-onset foveomacular vitelliform dystrophy.

Sebastian Martinez-Castillo

Abstract


Purpose: We report a case of adult-onset foveomacular vitelliform dystrophy (AOFVD) complicated with atrophic involution and subsequent choroidal neovascularization (CNV) and treated with intravitreal ranibizumab.

Design: Case Report

Methods: A 71-year-old woman diagnosed with AOFVD experienced a progression of the vitelliform lesion to the atrophic stage in her left eye immediately after cataract surgery. Best corrected visual acuity (BCVA) decreased from 0.5 to 0.16. Ten months later, the patient was referred with new worsening of her visual acuity (0.05) and metamorphopsia. The spectral-domain optical coherence tomography (SD-OCT) confirmed the presence of type 2 CNV next to the atrophic area. The patient was treated with 2 monthly injections of ranibizumab.

Results: SD-OCT images improved significantly and her BCVA increased to 0.20 associated with subjective improvement of metamorphopsia.

Conclusion: Ranibizumab may be effective for CNV in patients with AOFVD.


Keywords


Adult-Onset Foveomacular Vitelliform Dystrophy; Retinal Atrophy; Choroidal Neovascularisation; Ranibizumab

Full Text:

Ranimizumab.PDF


DOI: https://doi.org/10.15324/vpa.v12i3.90

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.